D and E . Additionally, the factors which regulate the balance of production between the inhibins and activins also represent a mechanism modulating activin A levels and thus its biological activity.
The involvement of activin and follistatin in the response to trauma and inflammation emerged from the capacity of activin, like TGF , to suppress T cell activation (Hedger et al. 1989) and from the rise in follistatin induced in response to surgical stress (Klein et al. 1993) . In the intervening years, a considerable body of evidence has accumulated to support the involvement of both activin and follistatin in inflammation and the acute phase reaction.
Tissue injury and inflammation are accompanied by the release of the cytokines interleukin (IL)-1, IL-6 and tumour necrosis factor (TNF ) from macrophages and stromal cells at the site of injury (Steel & Whitehead 1994) . These cytokines, in turn, act at systemic sites, in particular the liver, to activate gene expression and the febrile response to injury, collectively known as the acute phase response (APR). The APR is a response to injury which induces numerous changes designed to protect the host and, in turn, to limit the potentially widespread actions of the cytokines and acute phase proteins released (Steel & Whitehead 1994) . The acute phase proteins (APP) that are up-regulated include agents which limit the inflammatory process, minimise tissue damage and facilitate the repair process. Included in this group are metal binding proteins, coagulation proteins, complement proteins, proteinase inhibitors and others such as serum amyloid A, serum amyloid P component and C-reactive protein. In addition, IL-1 and IL-6 act on the pituitary-adrenal axis to induce glucocorticoid secretion, which facilitates APP secretion and inhibits cytokine gene expression by monocytes and macrophages.
Several observations have linked the activin A/follistatin system to the modulation of the APR. While our studies established that the pattern of follistatin secretion was similar to that of an APP (Klein et al. 1993 , Phillips et al. 1996 , its role in this process remained unclear, since no data were available to demonstrate a role for activin A in this process, partly due to difficulties in assaying this protein. However, recently Brosh et al. (1995) showed that activin A was an IL-6 antagonist at a number of sites, and established that this action was probably mediated by interference with the signal transduction mechanism of IL-6. Further, activin A decreases IL-1 production and induces IL-1 receptor antagonist secretion by human monocytic cells, effectively acting as a negative IL-1 modulator (Ohguchi et al. 1998) . However, it is important to note that activin A stimulates IL-6 production by monocytes (Yamashita et al. 1993) .
The demonstration that activin A can antagonise the actions of both IL-1 and IL-6 raises the possibility that activin A acts as an anti-inflammatory agent both locally at the site of injury or infection and at peripheral sites such as the liver. In turn, the actions of activin A, a pleotrophic cytokine or growth factor, is subject to regulation by a multiplicity of systems, one of which is its binding protein, follistatin.
What are the roles of activin A and follistatin in inflammation and the APR?

At the site of tissue injury
Increased activin A expression, as either mRNA or protein, has been shown at sites of tissue injury, in chronic inflammatory bowel disease or in synovial fluid from patients with inflammatory arthropathy (Hubner et al. 1997 , Yu et al. 1998 . The likely cellular localisation at these sites is fibroblasts (Hubner et al. 1997) , but other studies have shown that macrophages and monocytes produce activin A in response to lipopolysaccharide (LPS) and proinflammatory cytokines such as interferon and granulocyte monocyte colony stimulating factor (Eramaa et al. 1992 , Shao et al. 1992 . At these sites, activin A has the potential to antagonise the local actions of IL-6 and IL-1. Additionally, activin A and follistatin are expressed in endothelial cells and follistatin has been shown to induce angiogenesis (Kozian et al. 1997) . The temporal and cellular expression of activin A and follistatin will be required to determine whether the differential regulation of these proteins after wound healing (Hubner et al. 1996) has a role to play in the control of vascular integrity after tissue injury or whether they are involved in the modulation of IL-1 and IL-6 at these sites.
In the circulation
Follistatin levels in the circulation rise 6-24 h post-surgery with peak levels at approximately 12 h in ewes (Klein et al. 1993) and in rams (Phillips et al. 1996) . Further, Michel et al. (1998) have shown that follistatin levels in the circulation are markedly elevated in patients with septicaemia.
Support for the concept that this rise in follistatin is linked to the APR emerges from studies which demonstrated that IL-1 injection could induce a similar circulating rise in this protein (Phillips et al. 1996) . Further, administration of LPS to sheep resulted in a marked increase in serum follistatin levels, showing the capacity of an inflammatory stimulus to increase follistatin expression (Klein et al. 1996) . However, during a sustained inflammatory stimulus induced by the administration of yeast to lambs, follistatin levels rose initially for about 24 h, but subsequently declined . The failure to sustain the increased follistatin expression may have been related to the intervention of other pathways regulating follistatin, since we showed that the weight loss sustained by the lambs in this experiment probably served as a negative regulator of follistatin. The source of follistatin secretion in the acute phase response still remains unclear. Hepatic parenchymal cells express follistatin mRNA and hepatoma cells (HepG2) can secrete follistatin in response to activin but not IL-1 ). However, Michel et al. (1996) showed that follistatin mRNA in endothelial cells increases markedly following LPS stimulation, raising the possibility that these cells may be the site of the follistatin response.
There are still no published data concerning systemic activin A levels in response to agents inducing the APR. The administration of LPS has been shown to cause an acute and rapid increase in activin A levels between 0·5 and 4 h later and this precedes the rise in follistatin (K L Jones, D M de Kretser & D J Phillips, unpublished observations). These data need to be expanded further to document changes in activin A levels resulting from a variety of stimuli.
The significance of the changes in circulating follistatin and activin A levels remains to be established. Given the capacity of activin A to antagonise the actions of IL-6 and IL-1, the increased serum levels of activin A may modulate the actions of these cytokines at many sites and, in particular, the stimulatory actions of these cytokines on acute phase protein production in the liver. Failure of activin A to modulate the actions of these cytokines may be linked to the continued elevated levels of some of the acute phase proteins which have been implicated in chronic disease states such as secondary amyloidosis (Steel & Whitehead 1994) . Additionally, activin A may stimulate erythroid and megakaryocyte differentiation in the bone marrow, negating the effects of infection and trauma at these sites (for review see Yu & Dolter 1997) .
It is unclear whether activin A can penetrate the blood-brain barrier, as microinfusions of activin A into the paraventricular nucleus in rats can cause the release of corticotrophin releasing hormone (CRH) and oxytocin (Plotsky et al. 1991) . The resultant stimulation of adrenal glucocorticoid secretion could exert modulatory influences on the APR and the inflammatory state. Further, LPS has been shown to induce cFOS expression at numerous central nervous system sites including the paraventricular nucleus and the nucleus tractus solitarius, which projects to the paraventricular nucleus and probably uses activin A as a neurotransmitter (Sawchenko et al. 1988 , Hare et al. 1995 .
In the liver
The APR is characterised by a marked increase in hepatic acute phase protein production under the influence of IL-1 and IL-6, and Brosh et al. (1995) have shown that activin A can inhibit the IL-6-induced stimulation of some of these proteins. In recent studies using HepG2 cells, we have shown that activin A can directly inhibit the secretion of haptoglobin and block the stimulatory action of IL-6 on this process, yet it could only inhibit 1-acid glycoprotein production indirectly by its antagonistic action on IL-6 (Russell et al. 1999) . Further, these studies showed that activin A stimulated HepG2 cell secretion of follistatin which, in turn, could modulate the action of activin. There is a need for further studies to document the actions of activin A on the full range of APR proteins, given their important role in modulating the body's response to the inflammatory or traumatic stimulus.
What is the integrative role of activin A and follistatin in the APR?
Given the complex nature of the APR and its importance for the ability of the body to respond to infection and trauma, it is not surprising that regulatory systems exist which set this process in motion and which, in turn, can limit its duration and extent. It has been recognised that the proinflammatory cytokines, IL-1, IL-6 and TNF , are involved in the activation of the APR (Fig. 1) . This brief review indicates that activin A, by its capacity to antagonise the actions of IL-1 and IL-6, represents an important modulator of the APR. This regulation is likely to occur at the site of injury and also at the liver. In turn, given the multifunctional role of activin A, its stimulation of follistatin at many sites provides a regulatory system to limit the duration of the actions of activin. It is clear that further work is required to test these hypotheses in whole animal experiments. Such studies would be enhanced by the availability of mice in which the relevant genes had been inactivated by homologous recombination. Unfortunately, the follistatin and activin A gene 'knock outs' do not survive significantly beyond birth (Matzuk et al. 1995a,b) . Further, the design of such experiments is curtailed by the very limited supplies of these proteins.
